Allied Minds prices IPO to raise £76m
This article was originally published in Scrip
US technology transfer firm Allied Minds has priced its IPO on the London Stock Exchange at 190p per share. The offer comprises around 44.3 million shares issued by the company, and around 17.4 million shares from selling shareholders. Allied Minds estimates it will bring in around £76.2m ($130.0m) net, less than the £83m it was targeting when it first announced its IPO plans in May.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.